Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2009 1
2013 1
2019 1
2021 1
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

7 results
Results by year
Filters applied: . Clear all
Page 1
Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC-Real World Efficacy.
Mouritzen MT, Carus A, Ladekarl M, Meldgaard P, Nielsen AWM, Livbjerg A, Larsen JW, Skuladottir H, Kristiansen C, Wedervang K, Schytte T, Hansen KH, Østby AC, Frank MS, Lauritsen J, Sørensen JB, Langer SW, Persson GF, Andersen JL, Frary JMC, Drivsholm LB, Vesteghem C, Christensen HS, Bjørnhart B, Pøhl M. Mouritzen MT, et al. Among authors: bjornhart b. Cancers (Basel). 2021 Sep 28;13(19):4846. doi: 10.3390/cancers13194846. Cancers (Basel). 2021. PMID: 34638329 Free PMC article.
Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study.
Mouritzen MT, Junker KF, Carus A, Ladekarl M, Meldgaard P, Nielsen AWM, Livbjerg A, Larsen JW, Skuladottir H, Kristiansen C, Wedervang K, Schytte T, Hansen KH, Østby AC, Frank MS, Lauritsen J, Sørensen JB, Langer SW, Persson GF, Andersen JL, Homann PH, Kristensen EB, Drivsholm LB, Bøgsted M, Christensen HS, Pøhl M, Bjørnhart B. Mouritzen MT, et al. Among authors: bjornhart b. Acta Oncol. 2022 Jan 11:1-8. doi: 10.1080/0284186X.2021.2023213. Online ahead of print. Acta Oncol. 2022. PMID: 35012430